Protara Therapeutics, Inc. (TARA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TARA Revenue Growth
TARA Revenue Analysis (2014–2025)
As of May 8, 2026, Protara Therapeutics, Inc. (TARA) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, TARA's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $2.9 million in 2014.
When compared to Healthcare sector peers including FOLD (+20.0% YoY), RARE (+13.3% YoY), and ACAD (+9.9% YoY). Compare TARA vs FOLD →
TARA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TARACurrent | $0 | - | - | - | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 PRTA | $10M | -58.0% | +62.6% | -1905.8% |
TARA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-362,000 | - | $-64,549,000 | - |
| 2024 | $0 | - | $0 | - | $-49,154,000 | - |
| 2023 | $0 | - | $-341,000 | - | $-43,613,000 | - |
| 2022 | $0 | - | $0 | - | $-67,062,000 | - |
| 2021 | $0 | - | $0 | - | $-47,489,000 | - |
| 2020 | $0 | - | $-196,000 | - | $-34,444,000 | - |
| 2019 | $0 | - | $-16,000 | - | $-15,254,000 | - |
| 2018 | $0 | - | $-115,000 | - | $-26,080,000 | - |
| 2017 | $0 | - | $-148,000 | - | $-30,362,000 | - |
| 2016 | $0 | - | $-123,000 | - | $-28,705,000 | - |
See TARA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TARA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TARA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTARA — Frequently Asked Questions
Quick answers to the most common questions about buying TARA stock.
Is TARA's revenue growth accelerating or slowing?
TARA TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is TARA's long-term revenue growth rate?
Protara Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is TARA's revenue distributed by segment?
TARA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.